These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 22228256)
1. Acceptance and opinions of Intanza/IDflu intradermal influenza vaccine in the Czech Republic and Turkey. Prymula R; Usluer G; Altinel S; Sichova R; Weber F Adv Ther; 2012 Jan; 29(1):41-52. PubMed ID: 22228256 [TBL] [Abstract][Full Text] [Related]
2. Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Eizenberg P; Booy R; Naser N; Mason G; Stamboulian D; Weber F Adv Ther; 2011 Aug; 28(8):640-9. PubMed ID: 21751080 [TBL] [Abstract][Full Text] [Related]
3. Acceptability of Intanza® 15 μg intradermal influenza vaccine in Belgium during the 2010-2011 influenza season. Dhont PA; Albert A; Brenders P; Podwapinska A; Pollet A; Scheveneels D; Tihon F; Verheyden I; Victor J; Samson SI Adv Ther; 2012 Jun; 29(6):562-77. PubMed ID: 22678831 [TBL] [Abstract][Full Text] [Related]
4. Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine: a survey of general practitioners and the general public in France and Germany. Arnou R; Frank M; Hagel T; Prébet A Adv Ther; 2011 Jul; 28(7):555-65. PubMed ID: 21626269 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of Intanza(®)/IDflu(®) intradermal influenza vaccine in South Korean adults: a multicenter, randomized trial. Hoon Han S; Hee Woo J; Weber F; Joo Kim W; Ran Peck K; Il Kim S; Hwa Choi Y; Myung Kim J Hum Vaccin Immunother; 2013 Sep; 9(9):1971-7. PubMed ID: 23778938 [TBL] [Abstract][Full Text] [Related]
6. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses. Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501 [TBL] [Abstract][Full Text] [Related]
7. Acceptance and safety of the intradermal influenza vaccine among the elderly in Italy: an on-field national study. Durando P; Alicino C; Alberti M; Sticchi L; Turello V; Marensi L; Caiazzo AL; Panico MG; Giugliano F; Parlato A; Peluso F; Sgricia S; Icardi G; Adv Ther; 2012 Apr; 29(4):312-26. PubMed ID: 22529024 [TBL] [Abstract][Full Text] [Related]
8. Fluzone(®) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults. Ansaldi F; de Florentiis D; Durando P; Icardi G Expert Rev Vaccines; 2012 Jan; 11(1):17-25. PubMed ID: 22149703 [TBL] [Abstract][Full Text] [Related]
9. Intanza (®) 9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age. Leroux-Roels I; Weber F Hum Vaccin Immunother; 2013 Jan; 9(1):115-21. PubMed ID: 23442585 [TBL] [Abstract][Full Text] [Related]
10. Intanza(®): a new intradermal vaccine for seasonal influenza. Atmar RL; Patel SM; Keitel WA Expert Rev Vaccines; 2010 Dec; 9(12):1399-409. PubMed ID: 21105776 [TBL] [Abstract][Full Text] [Related]
11. Nine μg intradermal influenza vaccine and 15 μg intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults. Nougarede N; Bisceglia H; Rozières A; Goujon C; Boudet F; Laurent P; Vanbervliet B; Rodet K; Hennino A; Nicolas JF Hum Vaccin Immunother; 2014; 10(9):2713-20. PubMed ID: 25483667 [TBL] [Abstract][Full Text] [Related]
12. Acceptability of fluzone intradermal vaccine to patients and vaccine administrators. Foy JE; Hendriksz T; Malouf P; Tobin A J Am Osteopath Assoc; 2013 Feb; 113(2):134-43. PubMed ID: 23412675 [TBL] [Abstract][Full Text] [Related]
13. A randomized control trial comparing immunogenicity, safety, and preference for self- versus nurse-administered intradermal influenza vaccine. Coleman BL; McGeer AJ; Halperin SA; Langley JM; Shamout Y; Taddio A; Shah V; McNeil SA Vaccine; 2012 Sep; 30(44):6287-93. PubMed ID: 22902784 [TBL] [Abstract][Full Text] [Related]
14. Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Ansaldi F; Durando P; Icardi G Expert Opin Biol Ther; 2011 Mar; 11(3):415-27. PubMed ID: 21299438 [TBL] [Abstract][Full Text] [Related]
15. Serum antibody responses after intradermal vaccination against influenza. Belshe RB; Newman FK; Cannon J; Duane C; Treanor J; Van Hoecke C; Howe BJ; Dubin G N Engl J Med; 2004 Nov; 351(22):2286-94. PubMed ID: 15525713 [TBL] [Abstract][Full Text] [Related]
16. Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers. Coleman BL; McNeil SA; Langley JM; Halperin SA; McGeer AJ Vaccine; 2015 Nov; 33(48):6635-40. PubMed ID: 26529074 [TBL] [Abstract][Full Text] [Related]
17. [New options of influenza vaccination]. Chlíbek R Cas Lek Cesk; 2010; 149(3):111-4. PubMed ID: 20429345 [TBL] [Abstract][Full Text] [Related]
18. Dose sparing with intradermal injection of influenza vaccine. Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318 [TBL] [Abstract][Full Text] [Related]
20. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. Holland D; Booy R; De Looze F; Eizenberg P; McDonald J; Karrasch J; McKeirnan M; Salem H; Mills G; Reid J; Weber F; Saville M J Infect Dis; 2008 Sep; 198(5):650-8. PubMed ID: 18652550 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]